TDOCTeladoc Health, Inc.
$5.78-27% 1Y
$5.78
$4.4752 weeks$9.71
The financials
Teladoc Health, Inc. by the numbers
Teladoc Health, Inc. (TDOC) reported revenue of $607M in Q2 2026 (quarter ended Jun 30, 2026), down 4.0% from the same quarter a year earlier. That came with a gross margin of 69% and net loss of $39M. For the full year FY2025, revenue was $2.53B (−1.5% year on year) and net income −$200M. Its largest product in Q2 2026 was Subscription Access Fees at $474M, 78% of the disclosed total, well ahead of Other at 22%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $607M | $632M | −4.0% |
| Gross profit | $416M | $441M | −5.7% |
| Operating income | −$37M | −$54M | n/a |
| Net income | −$39M | −$33M | n/a |
| Diluted EPS | −$0.21 | −$0.19 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Subscription Access Fees | $474M | 78% |
| Other | $133M | 22% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $606.9M (-1.1%)
Other grew +23% year on yearSubscription Access Fees -9.4% year on year
Segment Latestquarter on quarteryear on year
- Subscription Access Fees$474.2M$474.2Mquarter on quarter -2.2%year on year -9.4%-2.2%-9.4%
- Other$132.7M$132.7Mquarter on quarter +2.7%year on year +23%+2.7%+23%
On our screens:Most shorted stocks
Health Information Services
Ranks #17 of 20 by RyuScore